Register for free to
view the full innovation profile.
EPA-L is a stable, safe endogenous Omega 3 (EPA) metabolite and microvascular dilator [ex vivo (Human), in vivo (rat)], reducing blood pressure (POC in MCT rats)
About
Despite advances in the treatment for PAH there is a continued need for additional effective and tolerable treatment options to improve quality of life and life expectancy. Alongside with the development of new vasodilators activating known signaling pathways there is a search for novel pathways and new therapeutic targets involved in disease pathogenesis. Dr Andrea Sapir, Head of Vascular Signaling Laboratory at MIGAL, is developing Omega 3 lactone (EPA L) as a new vasodilator for PAH. It is an endogenous EPA metabolite with favorable safety profile, chemically stable and enzymatically stable. EPA-L activities observed in completed experiments: • Vasodilator of human arteries in dose-dependent matter • Restores human microvascular dysfunction • New Mode of Action potential new vasodilating signaling pathway : - NO independent - endothelial dependent • POC in rat PAH model • Data for in vivo activity restoring arterial morphology (remodeling) Dr Sapir’s group is in collaboration with another university on an oral formulation of the EPA-L in nanocapsules, potentially allowing highly targeted delivery. The molecule has potential for treating other disorders/conditions associated with microvascular disfunction.
Key Benefits
- New Mode of Action: potential new vasodilating signaling pathway (NO independent, endothelial dependent) - IP Status: US, EU, China and Canada - ongoing review process; loss of exclusivity - 2039 - Possibility of highly targeted oral delivery via nanoencapsulation
Applications
Treatment for Pulmonary Arterial Hypertension; Treating other disorders/conditions associated with microvascular dysfunction; Preventing, reducing the risk of developing cardiac condition associated with microvascular dysfunction.